10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

10x Genomics (NASDAQ:TXG) issued its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06, Zacks reports. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The firm had revenue of $166.03 million for the quarter, compared to analyst estimates of $160.35 million. During the same period in the previous year, the business earned ($0.40) EPS. The company’s revenue was up .6% compared to the same quarter last year.

Here are the key takeaways from 10x Genomics’ conference call:

• Single-cell and spatial consumables showed strong momentum — reaction volumes grew double-digits driven by adoption of FLEX APEX, and spatial consumables rose 14% as Xenium adoption expanded across customers.
• Management reinstated full-year 2026 revenue guidance of $600–$625M, implying roughly 0–4% growth (ex‑litigation) with the midpoint assuming flat Chromium consumables and double-digit spatial growth.
• Instrument revenue remains a drag, down 36% in Q4 (Chromium down 44%), and the company expects ongoing capital expenditure constraints to keep instrument sales pressured in 2026.
• Financials strengthened — cash rose by about $130M to $523M, Q4 gross margin was 68%, and operating expenses fell 18%, giving the company more flexibility to invest while managing costs.

10x Genomics Price Performance

Shares of TXG stock opened at $17.51 on Friday. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of -28.24 and a beta of 2.24. The company’s fifty day simple moving average is $18.66 and its two-hundred day simple moving average is $15.57. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $23.56.

Insiders Place Their Bets

In other 10x Genomics news, CFO Adam Taich sold 11,888 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $225,872.00. Following the completion of the transaction, the chief financial officer owned 297,385 shares of the company’s stock, valued at approximately $5,650,315. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Benjamin J. Hindson sold 8,283 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $157,377.00. Following the completion of the transaction, the insider owned 432,605 shares of the company’s stock, valued at $8,219,495. This represents a 1.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 33,432 shares of company stock valued at $635,208 over the last 90 days. Insiders own 9.39% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

A number of institutional investors have recently bought and sold shares of the stock. Certuity LLC purchased a new stake in shares of 10x Genomics during the 3rd quarter worth $226,000. Orion Porfolio Solutions LLC bought a new position in 10x Genomics in the second quarter worth about $158,000. CANADA LIFE ASSURANCE Co raised its holdings in 10x Genomics by 167.9% in the second quarter. CANADA LIFE ASSURANCE Co now owns 22,069 shares of the company’s stock worth $256,000 after purchasing an additional 13,831 shares in the last quarter. Vident Advisory LLC purchased a new stake in shares of 10x Genomics during the second quarter valued at about $162,000. Finally, M&T Bank Corp bought a new stake in shares of 10x Genomics in the 2nd quarter valued at about $241,000. 84.68% of the stock is owned by institutional investors.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q4 results: 10x Genomics reported EPS of ($0.13), beating consensus for a larger loss, and revenue topped estimates — a clear short-term fundamental beat that supports upside if execution continues. Read More.
• Positive Sentiment: Strategic collaboration: A UK-backed PharosAI cancer data project will use 10x’s Xenium spatial platform — a potential long-term demand driver and validation of Xenium’s value in large-scale research. Read More.
• Neutral Sentiment: FY‑2026 revenue outlook: Management gave revenue guidance of $600M–$625M for 2026, which overlaps consensus (~$624M) but leaves limited upside vs. expectations; that makes guidance essentially in-line to modestly conservative. Read More.
• Neutral Sentiment: Short‑interest report appears unreliable: Published short‑interest entries show large increases but display zero/NaN values and a 0.0 days‑to‑cover figure — treat that data as noisy and not a clear market signal. (Internal/market data entries)
• Negative Sentiment: Pricing‑strategy risks and guidance clarity: Coverage notes a new pricing strategy is debuting this quarter, which creates execution risk for revenue/margin cadence; reports also show EPS guidance was not clearly provided in the update, which can amplify investor uncertainty and short‑term selling pressure. Read More.

Analyst Upgrades and Downgrades

TXG has been the topic of a number of research reports. UBS Group boosted their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Wall Street Zen lowered shares of 10x Genomics from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Leerink Partners decreased their price target on shares of 10x Genomics from $22.00 to $20.00 and set a “market perform” rating for the company in a research report on Tuesday, January 27th. Piper Sandler raised their price target on shares of 10x Genomics from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Finally, Canaccord Genuity Group boosted their target price on shares of 10x Genomics from $19.00 to $20.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and a consensus target price of $17.04.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.